Sustainable with safety: tbm hightech control receives the EcoVadis bronze medal
Sustainable action is essential in order to fulfil our responsibility for future generations. Sustainability means far m…
Endeavour Silver Announces Expansion into Peru with Acquisition of Minera Kolpa, Copper Stream and Bought Deal Financing
All dollar amounts are stated in United States (U.S.) Dollars unless otherwise noted. Endeavour Silver Corp. (“Endeavou…
Millennial Potash Initiates Phase 2 Drilling Program at its Banio Potash Project in Gabon
Millennial Potash Corp. (TSX.V:MLP, OTCQB:MLPNF, FSE: X0D) (“MLP”, “Millennial” or the “Company”) - https://www.commodit…
USU Listed for the First Time in the Gartner® Market Guide for Infrastructure Monitoring Tools 2025
The internationally recognized market research firm Gartner® has published the Market Guide for Infrastructure Monitorin…
HEALWELL gibt bevorstehende Ausübung einer Kaufoption durch WELL Health bekannt
HEALWELL AI Inc. („HEALWELL“ oder das „Unternehmen“) (TSX: AIDX, OTCQX: HWAIF), ein Unternehmen für künstliche Intellige…
Millennial Announces Closing Private Placement for Total Proceeds of $4,929,200
Millennial Potash Corp. (TSX.V:MLP, OTCQB:MLPNF, FSE: X0D) (“MLP", “Millennial” or the “Company”) - https://www.commodit…
TME Pharma provides results of fifth exercise of Warrants Z
556 Warrants Z were exercised resulting in the issuance of 695 new ordinary shares Outstanding 2,810,092 Warrants Z re…
4SC provides results for financial year 2024 and outlook for 2025
4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 202…
Ubisoft accelerates its transformation by Laying Foundation for new operating model with the creation of a Subsidiary and Injection of €1.16bn of cash from selected investor Tencent
Today, Ubisoft announced that it is accelerating its transformation by taking an important step in rapidly evolving its…
Immatics Announces Full Year 2024 Financial Results and Business Update
Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients;…